References
- Wang BC, Zhang WX, Kuang BH etc. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. PLoS One 2022;17(10):e0275919.
- Harada C, Kawaguchi T, Ogata-Suetsugu S etc. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med 2011;183(6):743-751.
- Gemma A, Kudoh S, Ando M etc. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 2014;105(12):1584-1590.
- Muller NL, White DA, Jiang H etc. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91 Suppl 2(Suppl 2):S24-30.
- Chang SC, Chang CY, Chang SJ etc. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Clin Lung Cancer 2013;14(1):55-61.
- Graham BL, Steenbruggen I, Miller MR etc. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019;200(8):e70-e88.
- Graham BL, Brusasco V, Burgos F etc. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017;49(1).
- Shi Y, Li J, Zhang S etc. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One 2015;10(11):e0143515.
- Sequist LV, Yang JC, Yamamoto N etc. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27):3327-3334.
- Fathana FB, Yunus F, Andarini SL etc. Prevalens penyakit paru obstruksi kronik (PPOK) dan emfisema berdasarkan pemeriksaan spirometri dan Computed Tomography Scanning (CT-Scan) toraks pada pasien kanker paru di Rumah Sakit Umum Pusat Persahabatan. Jakarta, Indonesia: University of Indonesia; 2019.
- Leo F, Solli P, Spaggiari L etc. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004;77(1):260-265; discussion 265.
- Takeda S, Funakoshi Y, Kadota Y etc. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? Ann Thorac Surg 2006;82(1):232-236.
- Pinson P, Klastersky J. The value of lung function measurements for the assessment of chemotherapy in lung cancer patients. Lung Cancer 1998;19(3):179-184.
- Yang Z, Hackshaw A, Feng Q etc. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer 2017;140(12):2805-2819.
- Lim SH, Lee JY, Sun JM etc. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. J Thorac Oncol 2014;9(4):506-511.
- Wu SG, Chang YL, Yu CJ etc. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res 2017;3(3).
- Bailey KL. The importance of the assessment of pulmonary function in COPD. Med Clin North Am 2012;96(4):745-752.